Daniel B. Kassel

Bristol-Myers Squibb (United States)

Papers

1

Total Citations

87

H-Index

1

About

Daniel B. Kassel is a pioneering figure in drug discovery and pharmaceutical research, best known for his transformative work in high-throughput ADME (Absorption, Distribution, Metabolism, and Excretion) profiling. His seminal 2004 paper, "Automated high throughput ADME assays for metabolic stability and cytochrome P450 inhibition profiling of combinatorial libraries," with 87 citations, laid the groundwork for integrating early-stage pharmacokinetic assessment into combinatorial chemistry workflows. Kassel’s major contribution lies in developing automated, miniaturized assays that enable rapid screening of metabolic stability and CYP inhibition—critical parameters for predicting drug safety and efficacy. This innovation dramatically accelerated lead optimization, reducing late-stage failures in drug development. His work has been widely adopted in both academic and industrial settings, influencing the design of modern ADME platforms. Beyond this, Kassel has been instrumental in advancing mass spectrometry-based techniques for bioanalysis, and his collaborative efforts have shaped best practices in preclinical drug metabolism. With a career spanning over two decades, his research continues to impact how scientists approach the early elimination of problematic compounds, making him a key figure in the quest for safer, more effective therapeutics.

Research Focus

Key Achievements

1
H-Index
1
Papers
87
Total Citations
87
Avg Citations/Paper
🏆 Most Cited Paper
Automated high throughput ADME assays for metabolic stability and cytochrome P450 inhibition profiling of combinatorial libraries
87 citations · 2004
📈 Most Prolific Year: 2004 (1 Papers)
🤝 Key Collaborators: 5
🏛 Institutions: Bristol-Myers Squibb (United States)

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 12 days ago